Date: 2015-04-01
Type of information: Licensing agreement
Compound: data from the Deciphering Developmental Disorders (DDD) study
Company: Oxford Gene Technology (UK) Wellcome Trust Sanger Institute (UK)
Therapeutic area: Genetic diseases - Rare diseases
Type agreement: licensing
Action mechanism:
Disease:
Details: * On April 1, 2015, Oxford Gene Technology (OGT), the molecular genetics company, announced that it has signed a license agreement with the Wellcome Trust Sanger Institute for access to data from the Deciphering Developmental Disorders (DDD) study. This study is a collaboration between the UK\'s National Health Service (NHS), the Wellcome Trust and the Wellcome Trust Sanger Institute to conduct genome wide screening of over 12,000 individuals with developmental disorders to uncover the underlying genetic aberrations. New technologies such as high-resolution microarrays and exome sequencing were used by the study to identify previously undetected genetic changes in the samples. The DDD study has successfully identified new areas of the genome as responsible for developmental disorders. OGT plans to use this ground-breaking information, combined with the latest updates from the International Collaboration for Clinical Genomics (ICCG) consortium, to develop its CytoSure Constitutional v3 range, an advance on OGT’s successful CytoSure ISCA arrays. The range will accurately identify both single nucleotide polymorphisms (SNPs) and copy number variation (CNV) for accurate identification of a broader range of genetic syndromes, detecting amplifications and deletions as well as regions of loss of heterozygosity (LOH). These newly identified genomic regions are included in OGT’s advanced array design, enabling more powerful analysis.
Financial terms:
Latest news:
